Research & Development
IQuity’s research efforts have demonstrated that autoimmune patients exhibit distinct RNA expression patterns in their blood. This critical breakthrough can improve a provider’s ability to detect autoimmune diseases and related conditions early. Providers can also use this technology in the clinic to examine possible cases of misdiagnosis.
The IQIsolate® Process
IQuity uses machine learning to develop algorithms that analyze RNA expression patterns found in a patient blood sample. The IQIsolate process measures expression of a set of genes to accurately determine if the expression pattern found in a patient’s blood sample is consistent with those found in disease.
Using the IQIsolate® process, IQuity developed and commercialized three RNA-based blood tests that distinguish between difficult to diagnose diseases. The Isolate® tests differentiate multiple sclerosis from other neurological diseases; IBS from Crohn’s and ulcerative colitis; and fibromyalgia from other rheumatic diseases with greater than 90% accuracy.
If you are looking for Decode Health AI for Identification of Chronic Disease Risk, CLICK HERE.
Clinical Testing Has Been Discontinued. Genomic Research Efforts Continue.
IQuity’s research continues with funding from the National Institutes of Health (NIH) through the Small Business Innovation Research (SBIR) grant program. Current projects are creating new tools to monitor treatment responses in multiple sclerosis and extend IQuity’s diagnostic capabilities beyond autoimmune disease into other neurodegenerative diseases like Alzheimer’s. Since the fall of 2018, IQuity has received a $320,000 grant from the National Institute on Aging (NIA) and most recently received a fast track SBIR grant of $1.1 million from the National Institute of Allergy and Infectious Disease (NIAID), to support the development of new disease monitoring approaches in multiple sclerosis.
IQuity’s research is focused on further enhancing disease detection using novel RNAs found in serum or in whole blood to identify autoimmune diseases and related syndromes. Recently, these studies have also extended to neurodegenerative diseases including Alzheimer’s. Using the RNA data collected, IQuity’s goal is to create an algorithm that can pinpoint these patients in the earliest stages of disease.
IQuity is developing new tools to help providers track how patients respond to treatment in multiple sclerosis. These tools will give providers new information to better recognize patients who are responding or not responding to therapy. Enhanced disease monitoring can improve outcomes and minimize the frequency and severity of damaging disease relapses.